Platelet inhibitory effects of OTC doses of naproxen sodium compared with prescription dose naproxen sodium and low-dose aspirin

References

• Zhang W, Moskowitz RW, Nuki G, et al. OARSI recommendations for the management of hip and knee osteoarthritis, Part II: OARSI evidence-based, expert consensus guidelines. Osteoarthritis Cartilage 2008;16:137-62
   PubMed Web of Science ®Google Scholar
• American College of Rheumatology Ad Hoc Group on Use of Selective and Nonselective Nonsteroidal Antiinflammatory Drugs. Recommendations for use of selective and nonselective nonsteroidal antiinflammatory drugs: An American College of Rheumatology white paper. Arthritis Rheum 2008;59:1058-73
   PubMed Web of Science ®Google Scholar
• Golden HE, Moskowitz RW, Minic M. Analgesic efficacy and safety of nonprescription doses of naproxen sodium compared with acetaminophen in the treatment of osteoarthritis of the knee. Am J Ther 2004;11:85-94
   PubMedGoogle Scholar
• Schiff M, Minic M. Comparison of the analgesic efficacy and safety of nonprescription doses of naproxen sodium and ibuprofen in the treatment of osteoarthritis of the knee. J Rheumatol 2004;31:1373-83
   PubMed Web of Science ®Google Scholar
• Boureau F, Schneid H, Zeghari N, et al. The IPSO study: ibuprofen, paracetamol study in osteoarthritis. A randomised comparative clinical study comparing the efficacy and safety of ibuprofen and paracetamol analgesic treatment of osteoarthritis of the knee or hip. Ann Rheum Dis 2004;63:1028-34
   PubMed Web of Science ®Google Scholar
• Capone ML, Tacconelli S, Sciulli MG, et al. Clinical pharmacology of platelet, monocyte, and vascular cyclooxygenase inhibition by naproxen and low-dose aspirin in healthy subjects. Circulation 2004;109:1468-71
   PubMed Web of Science ®Google Scholar
• Bombardier C, Laine L, Reicin A, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med 2000;343:1520-8
   PubMed Web of Science ®Google Scholar
• Kearney PM, Baigent C, Godwin J, et al. Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials. Br Med J 2006;332:1302-8
   PubMed Web of Science ®Google Scholar
• Henández-Diáz S, Varas-Lorenzo C, García Rodríguez LA. Non-steroidal antiinflammatory drugs and the risk of acute myocardial infarction. Basic Clin Pharmacol Toxicol 2006;98:266-74
   PubMed Web of Science ®Google Scholar
• McGettigan P, Henry D. Cardiovascular risk and inhibition of cyclooxygenase. A systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2. J Am Med Assoc 2006;296:1633-44
   PubMed Web of Science ®Google Scholar
• Singh G, Wu O, Langhorne P, et al. Risk of acute myocardial infarction with nonselective non-steroidal anti-inflammatory drugs: a meta-analysis. Arthritis Res Ther 2006;8:R153
   PubMed Web of Science ®Google Scholar
• Farkouh ME, Greenberg JD, Jeger RV, et al. Cardiovascular outcomes in high risk patients with osteoarthritis treated with lumiracoxib, ibuprofen, or naproxen. Ann Rheum Dis 2007;66:764-70
   PubMed Web of Science ®Google Scholar
• Cryer B, Berlin RG, Cooper SA, et al. Double-blind, randomized, parallel, placebo-controlled study of ibuprofen effects on thromboxane B2 concentrations in aspirin-treated healthy adult volunteers. Clin Ther 2005;27:185-91
   PubMed Web of Science ®Google Scholar
• Alessandrini P, Avagaro P, Bittolo BG, et al. Physiologic variables affecting thromboxane B2 production in human whole blood. Thromb Res 1985;37:1-8
   PubMed Web of Science ®Google Scholar
• Reilly IA, Fitzgerald GA. Inhibition of thromboxane formation in vivo and ex vivo: implications for therapy with platelet inhibitory drugs. Blood 1987;69:180-6
   PubMed Web of Science ®Google Scholar
• Catella F, Fitzgerald GA. Paired analysis of urinary thromboxane B2 metabolites in humans. Thromb Res 1987;47:647-56
   PubMed Web of Science ®Google Scholar
• Van Hecken A, Schwartz JI, Depré M, et al. Comparative inhibitory activity of rofecoxib, meloxicam, diclofenac, ibuprofen, and naproxen on COX-2 versus COX-1 in healthy volunteers. J Clin Pharmacol 2000;40:1109-20
   PubMed Web of Science ®Google Scholar
• Shah AA, Thjodleifsson B, Murray FE, et al. Selective inhibition of COX-2 in humans is associated with less gastrointestinal injury: a comparison of nimesulide and naproxen. Gut 2001;48:339-46
   PubMed Web of Science ®Google Scholar
• FDA Advisory Committee Background Information, presented to Arthritis Advisory Committee, February 8, 2001. Available at: http://www.fda.gov/ohrms/dockets/ac/01/briefing/3677b2_01_merck.pdf [Last accessed 11 May 2009]
   Google Scholar
• Capone ML, Tacconelli S, Sciulli MG, et al. Human pharmacology of naproxen sodium. J Pharmacol Exp Ther 2007;322:453-60
   PubMed Web of Science ®Google Scholar
• Hinz B, Cheremina O, Besz D, et al. Impact of naproxen sodium at over-the-counter doses on cyclooxygenase isoforms in human volunteers. Int J Clin Pharmacol Ther 2008;46:180-6
   PubMed Web of Science ®Google Scholar
• Chou R, Helfand M, Peterson K, et al. Comparative effectiveness and safety of analgesics for osteoarthritis. Comparative effectiveness review No. 4. (Prepared by the Oregon Evidence-based Practice Center under Contract No. 290-02-0024.) Rockville, MD: Agency for Healthcare Research and Quality. September 2006. Available at: http://www.effectivehealthcare.ahrq.org/repFiles/AnalgesicsFinal.pdf [Last accessed 11 May 2009]
   Google Scholar
• ADAPT Research Group. Cardiovascular and cerebrovascular events in the randomized, controlled Alzheimer's disease anti-inflammatory prevention trial (ADAPT). PLoS Clin Trials 2006;1:e33
   Google Scholar